These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33854624)

  • 1. Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis.
    Chen X; Gao Y; Zhang G; Li B; Ma T; Ma Y; Wang X
    J Cancer; 2021; 12(9):2643-2653. PubMed ID: 33854624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
    Hein A; Lambrechts D; von Minckwitz G; Häberle L; Eidtmann H; Tesch H; Untch M; Hilfrich J; Schem C; Rezai M; Gerber B; Dan Costa S; Blohmer JU; Schwedler K; Kittel K; Fehm T; Kunz G; Beckmann MW; Ekici AB; Hanusch C; Huober J; Liedtke C; Mau C; Moisse M; Müller V; Nekljudova V; Peuteman G; Rack B; Rübner M; Van Brussel T; Wang L; Weinshilboum RM; Loibl S; Fasching PA
    Int J Cancer; 2015 Dec; 137(12):2981-8. PubMed ID: 26100253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials.
    Wei J; Luo Y; Fu D
    Onco Targets Ther; 2018; 11():9049-9059. PubMed ID: 30588017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
    Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    Sun Z; Lan X; Xu S; Li S; Xi Y
    BMC Cancer; 2020 Mar; 20(1):180. PubMed ID: 32131770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials.
    Nahleh Z; Botrus G; Dwivedi A; Jennings M; Nagy S; Tfayli A
    Mol Clin Oncol; 2019 Mar; 10(3):357-365. PubMed ID: 30847174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials.
    Liu X; Liu X; Qiao T; Chen W; Yuan S
    Onco Targets Ther; 2016; 9():3771-81. PubMed ID: 27445484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
    Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
    Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
    Liang X; Li H; Coussy F; Callens C; Lerebours F
    Chin J Cancer Res; 2019 Aug; 31(4):586-600. PubMed ID: 31564802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
    Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
    Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
    PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Martín M; Loibl S; Hyslop T; De la Haba-Rodríguez J; Aktas B; Cirrincione CT; Mehta K; Barry WT; Morales S; Carey LA; Garcia-Saenz JA; Partridge A; Martinez-Jañez N; Hahn O; Winer E; Guerrero-Zotano A; Hudis C; Casas M; Rodriguez-Martin C; Furlanetto J; Carrasco E; Dickler MN; ; ;
    Eur J Cancer; 2019 Aug; 117():91-98. PubMed ID: 31276981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
    Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
    J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.